Proton pump

Serious Concerns About Frequent Heartburn Medications Spurs Demand for Healthy Alternatives

Retrieved on: 
Thursday, October 26, 2023
Proton, Sprouts, Whole Foods Market, Amazon (company), Indigestion, Proton-pump inhibitor, Stagnation, Food, PPI, News, Dementia, Heartburn, Proton pump, Human, Betaine, Marketing, Confusion, Diet, CVS, Dietary supplement

VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica, a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief. This move comes in response to the recent revelation of a study linking long-term usage of Proton Pump Inhibitors (PPIs) to potential health risks, including dementia. With a commitment to providing safe and effective solutions, Enzymedica offers consumers a variety of options that not only relieve symptoms of occasional heartburn resulting from food and diet choices, but also promote overall digestive wellness.

Key Points: 
  • VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica , a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief.
  • The heartburn solutions category has faced stagnation due to a lack of innovation, concerns about drug side effects and confusion surrounding the frequent, long-term usage of PPIs and other acid inhibitors.
  • The recent study shedding light on potential health risks associated with PPIs has left consumers seeking trustworthy alternatives that prioritize their well-being.
  • These products offer consumers a reliable and convenient way to address their occasional heartburn concerns with natural, science-backed solutions.

Global Digestive Remedies Market 2023: Sector is Expected to Reach $22.53 Billion by 2028 at a CAGR of 3.3% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 1, 2023
Health, Pharmaceutical, Proton, Online, Antacid, Prevalence, IBD, Internet, Overalls, Laxative, Ageing, Tablet, Constipation, Meal, Capsule, PPI, Market, Motion Sickness, Enzyme, IBS, Pharmacy, Heartburn, Distribution, Growth, Online and offline, Proton pump, Proton-pump inhibitor, Dietary supplement, GERD, Others, Powder

By Formulation: Based on the formulation, the global digestive remedies market can be segmented into four segments: Capsules, Tablets, Powder, and Others.

Key Points: 
  • By Formulation: Based on the formulation, the global digestive remedies market can be segmented into four segments: Capsules, Tablets, Powder, and Others.
  • By Distribution Channel: The global digestive remedies market can be divided into three segments based on distribution channel: Pharmacies & Drugstores, Online Providers, and Others.
  • By End User: The global digestive remedies market can be divided into two segments according to end user: Adult, and Pediatric.
  • In 2022, North America dominated the global digestive remedies market due to the high prevalence of digestive disorders.

Implantica Applauded by Frost & Sullivan for Transforming Gastroesophageal Reflux Disease Treatment with Its Revolutionary Implant RefluxStop™

Retrieved on: 
Thursday, June 16, 2022
Proton, Proton pump, GERD, Population, Industry, Stomach, Abdomen, Cancer, PPI, American College of Gastroenterology, CE, Gastroesophageal reflux disease, Achievement, Gastroenterology, Dysphagia, American College, Leadership, Adoption, Hospital, Growth, Adenocarcinoma, Proton-pump inhibitor, Frost, Heartburn, Surgeon, Thorax, Quality of life, Neeraj, Diaphragm, Enzyme inhibitor, Death, Patient, Industry analyst, Esophagitis, Movement, Barrett's esophagus, Patient safety, Awareness, SAN, Prevalence, Esophagus, Risk, Frost & Sullivan, Medical device, EU

SAN ANTONIO, June 16, 2022 /PRNewswire/ --– Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device. The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment. The device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of commonly used drug treatment, Proton Pump Inhibitors (PPIs) and current surgical methods for treating acid reflux disease. The RefluxStop device is placed outside of the top part of the stomach (fundus wall) during laparoscopic surgery, reconstructing the angle of His, an acute angle at the esophagogastric junction. Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.

Key Points: 
  • SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device.
  • The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment.
  • Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.
  • Click here to view the full multimedia release: https://best-practices.frost.com/implantica/
    According to a recently published global study in Nature medical journal, there are more than 1 Billion people suffering from reflux disease.

Implantica Applauded by Frost & Sullivan for Transforming Gastroesophageal Reflux Disease Treatment with Its Revolutionary Implant RefluxStop™

Retrieved on: 
Thursday, June 16, 2022
Proton, Proton pump, GERD, Population, Industry, Stomach, Abdomen, Cancer, PPI, American College of Gastroenterology, CE, Gastroesophageal reflux disease, Achievement, Gastroenterology, Dysphagia, American College, Leadership, Adoption, Hospital, Growth, Adenocarcinoma, Proton-pump inhibitor, Frost, Heartburn, Surgeon, Thorax, Quality of life, Neeraj, Diaphragm, Enzyme inhibitor, Death, Patient, Industry analyst, Esophagitis, Movement, Barrett's esophagus, Patient safety, Awareness, SAN, Prevalence, Esophagus, Risk, Frost & Sullivan, Medical device, EU

SAN ANTONIO, June 16, 2022 /PRNewswire/ --– Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device. The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment. The device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of commonly used drug treatment, Proton Pump Inhibitors (PPIs) and current surgical methods for treating acid reflux disease. The RefluxStop device is placed outside of the top part of the stomach (fundus wall) during laparoscopic surgery, reconstructing the angle of His, an acute angle at the esophagogastric junction. Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.

Key Points: 
  • SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device.
  • The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment.
  • Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.
  • Click here to view the full multimedia release: https://best-practices.frost.com/implantica/
    According to a recently published global study in Nature medical journal, there are more than 1 Billion people suffering from reflux disease.

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022
Health, Pharmaceutical, Proton, Joint Medical Service (Germany), Reckitt, Constipation, Irritable bowel syndrome, Population, Ageing, Antiemetic, Daiichi Sankyo, Ulcerative colitis, Rockies Express Pipeline, Degenerative disease, Sucralfate, Proton-pump inhibitor, Antibody, Diverticular disease, Bayer, Route of administration, COVID-19, Prescription drug purchasing pool, Patent, Johnson & Johnson, Inflammatory bowel disease, Peptide, Procter & Gamble, WHO, Anal fissure, Hemorrhoid, Antacid, Heartburn, Organization, Eli Lilly, Takeda Pharmaceutical Company, Proton pump, Protein, Antidiarrhoeal, CAGR, Growth, Abbott Laboratories, Gastrointestinal tract, Fine chemical, Dietary supplement, Pharmaceutical industry, Misoprostol

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Worldwide GERD Therapeutics Industry to 2026 - Featuring Phathom Pharmaceuticals, Eisai and Takeda Pharmaceutical Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, September 10, 2021
Health, Pharmaceutical

The market of GERD is very large in the US and in European countries and mostly catered by PPIs.

Key Points: 
  • The market of GERD is very large in the US and in European countries and mostly catered by PPIs.
  • High incidence of obesity-driven GERD and innovation in drugs in GERD treatments are factors that have helped cement the potential of the North America GERD therapeutics market.
  • Global Gastroesophageal Reflux Disease Therapeutics Market: An Analysis
    5.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Drug Type
    6.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Distribution Channel
    7.
  • Global Gastroesophageal Reflux Disease Therapeutics Market: Regional Analysis
    7.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Region
    8.

Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study

Retrieved on: 
Friday, November 6, 2020
Branches of biology, Body fluids, Digestive system, Acids, Gastric acid, Transport proteins, Stomach, Proton pump

Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall.

Key Points: 
  • Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall.
  • The bridging study assessed pharmacokinetic and pharmacodynamic profiles of Fexuprazan in healthy Korean, Caucasian, and Japanese adults at the Seoul National University Hospital.
  • These study results are expected to accelerate our partnership efforts to quickly commercialize Fexuprazan in global markets, including the US and Europe."
  • The study results showed that Fexuprazan has 99% cure rate after 8 weeks of treatment and confirmed it is well-tolerate.

Global Proton Pump Inhibitors Market 2019-2024 by OTC (Omeprazole, Lansoprazole, Esomeprazole, Others) & Prescription (Rabeprazole, Dexlansoprazole, Pantoprazole, & Others)

Retrieved on: 
Wednesday, April 17, 2019
Proton pump inhibitors, Chemical compounds, Gastroenterology, PROTON Holdings, Proton pump, Organic compounds

DUBLIN, April 17, 2019 /PRNewswire/ -- The "Proton Pump Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 17, 2019 /PRNewswire/ -- The "Proton Pump Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.
  • Proton pump inhibitors are the widely prescribed drugs, and increased PPI use has been observed in the US ambulatory settings.
  • The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market.